Cntfr Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | CNTFR |
|---|
| Full Name | Ciliary Neurotrophic Factor Receptor |
|---|
| Chromosomal Location | 9p13.3 |
|---|
| NCBI Gene ID | 1024 |
|---|
| OMIM | 118425 |
|---|
| Ensembl ID | ENSG00000122756 |
|---|
| UniProt | P26447 |
|---|
| Protein | CNTFR Protein |
|---|
The CNTFR gene encodes the ciliary neurotrophic factor receptor (CNTFRα), a member of the cytokine receptor family. CNTFR is a critical receptor for CNTF (Ciliary Neurotrophic Factor) and plays essential roles in motor neuron survival, synaptic plasticity, and neuroprotection.
CNTFRα is a glycosylated cell surface receptor:
- Extracellular cytokine-binding domain (CBD)
- Single transmembrane domain
- Cytoplasmic signaling domain
- Forms multimeric complexes with signal-transducing subunits
CNTFR signals through multiple pathways:
- JAK/STAT pathway: JAK1/TYK2 activation → STAT3 phosphorylation → nuclear translocation
- MAPK/ERK pathway: Ras/Raf/MEK/ERK cascade
- PI3K/Akt pathway: Cell survival signaling
CNTFR is expressed in:
- CNTFR expression reduced in ALS motor neurons
- CNTF/CNTFR signaling impairment in ALS pathogenesis
- CNTF delivery trials in ALS showed some benefit
- Gene therapy approaches to enhance CNTFR signaling
- Astrocytic CNTFR dysfunction contributes to non-cell autonomous toxicity
- CNTF/CNTFR system important for motor neuron survival
- Reduced CNTFR expression in SMA models
- Therapeutic potential of CNTF delivery
- Combination approaches with SMN-targeted therapies
- CNTFR involved in cholinergic neuron survival
- Neuroprotective effects against Aβ toxicity
- Dysregulated in AD brain
- Potential therapeutic target
- CNTF/CNTFR protects dopaminergic neurons
- Neuroprotective in 6-OHDA and MPTP models
- Blood-brain barrier penetration challenges
- Delivery methods under investigation
¶ Stroke and Brain Injury
- CNTFR upregulation after injury
- Neuroprotective effects in ischemic models
- Promotes neural repair
- CNTF/CNTFR involved in mood regulation
- Antidepressant effects of CNTF
- Fast-acting antidepressant mechanisms
| Approach |
Status |
Notes |
| CNTF Delivery |
Clinical (ALS) |
Limited by side effects |
| CNTFR Agonists |
Preclinical |
Enhanced stability |
| Gene Therapy (AAV-CNTF) |
Preclinical |
Long-term expression |
| Small Molecule Modulators |
Research |
Development stage |
The study of Cntfr Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:7544442 - CNTFR structure and function
- PMID:8798751 - CNTF/CNTFR in ALS
- PMID:10625676 - CNTFR in Parkinson's disease models
- PMID:11025718 - CNTFR in Alzheimer's disease
- PMID:23498851 - CNTFR gene therapy approaches
The mammillotegmental tract (MTT) connects the mammillary bodies to the tegmental nuclei of the midbrain, forming a critical component of the Papez circuit for memory consolidation. This pathway:
- Receives inputs from the hippocampal formation via the fornix
- Integrates head direction and spatial information
- Projects to the dorsal tegmental nucleus (DTN)
- Contributes to REM sleep generation and spatial memory
Alzheimer's Disease: The mammillary bodies and their connections are early targets in AD, with neurofibrillary tangles found in these structures from early disease stages. Damage to the mammillotegmental pathway contributes to the characteristic memory deficits in AD.
Parkinson's Disease: Dysfunction in this pathway may contribute to the spatial navigation deficits observed in PD patients, particularly in tasks requiring environmental orientation.
Korsakoff Syndrome: Thiamine deficiency in Wernicke-Korsakoff syndrome specifically damages the mammillary bodies, disrupting the mammillotegmental tract and causing profound anterograde amnesia.
The mammillotegmental tract contains:
- GABAergic projections from the medial mammillary nucleus
- Glutamatergic projections from the lateral mammillary nucleus
- Modulatory cholinergic components
The mammillary bodies have been explored as potential DBS targets for memory disorders, though results have been mixed.
Cholinergic and GABAergic modulators may help restore function in damaged mammillotegmental circuits.
Spatial memory training and environmental navigation exercises may help compensate for dysfunction in this pathway.
- Vann SD. Re-evaluating the role of the mammillary bodies in memory. Brain. 2010;133(8):2333-2349.
- Aggleton JP. Understanding mammillary body function. Nat Rev Neurosci. 2008;9(6):432-444.
- Ishunina TA. Mammillary body atrophy in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007;78(6):596-601.
- Marker DF. Mammillotegmental tract lesions. Brain Res. 1985;327(1-2):271-277.
- Kril JJ. Mammillary body lesions in Wernicke-Korsakoff syndrome. Acta Neuropathol. 1997;93(4):366-371.
- Bunce D. Mammillary body atrophy and memory impairment. Neuropsychology. 2003;17(3):462-469.
- Guldin WO. Connections of the mammillary body in the rat. J Comp Neurol. 1981;203(3):525-543.
- Shibata H. Mammillotegmental projections to the dorsal tegmental nucleus. J Comp Neurol. 1992;323(2):281-290.